VivoSeq
Gastroenterology

Sclerosing Cholangitis

46

Pipeline Programs↗

15

Active Trials↗

32

Companies Involved↗

Sclerosing Cholangitis is a moderately active landscape with 46 programs across 32 companies. The most active players are Salix, Takeda, Merck & Co.. 5 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

60/100

Pipeline Velocity

19/100

Mech. Concentration

15/100

Completion Rate

72/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Salix

2 programs

Phase 1Takeda logo

Takeda

1 program

Phase 1Merck & Co. logo

Merck & Co.

1 program

Phase 1T

Triax

1 program

Phase 1AstraZeneca logo

AstraZeneca

1 program

Phase 1Daewoong Pharmaceutical Co. LTD. logo

Daewoong Pharmaceutical Co. LTD.

1 program

Phase 1

Pipeline

Programs by Phase

Analysis

Modality Breakdown

94%

Small molecule

47 of 50 classified programs — the dominant modality here.

6%ALL OTHERSMonoclonal antibody12%Protein / enzyme12%Cell therapy12%

Small molecule leads; the ring shows all 50 classified programs, each share of the total. Modality classified for 100% of 53 pipeline programs.

Analysis

Trial Status

57

clinical trials

Completed26 · 46%
Recruiting7 · 12%
Unknown status6 · 11%
Terminated6 · 11%
Not yet recruiting4 · 7%
Active, not recruiting4 · 7%
Other4 · 7%

Clinical Trials

Trial Activity

57 trials

Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin
Recruiting·—·Phase 1·NCT02137668·200 enrolled
Vancomycin in Primary Sclerosing Cholangitis in Italy
Recruiting·UUniversity of Milano Bicocca·Phase 2·NCT05876182·84 enrolled
FAecal Microbiota Transplantation in primaRy sclerosinG chOlangitis
Recruiting·UUniversity of Birmingham·Phase 2·NCT06286709·58 enrolled
A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC)
Recruiting·Takeda logoTakeda·Phase 1·NCT07229911·134 enrolled
Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation
Recruiting·MMayo Clinic·Phase 2·NCT06905054·80 enrolled
Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis.
Recruiting·—·Phase 2·NCT05295680·24 enrolled
Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study
Recruiting·SStanford University·Phase 1·NCT05912387·15 enrolled
Effect of Simvastatin on the Prognosis of Primary Primary Sclerosing Cholangitis (PSC)
Active, not recruiting·—·Phase 3·NCT04133792·571 enrolled
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)
Active, not recruiting·MMirum Pharmaceuticals, Inc.·Phase 2·NCT04663308·182 enrolled
A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.
Active, not recruiting·Ipsen logoIpsen·Phase 2·NCT05627362·68 enrolled
CS0159 in Chinese Patients With PSC (Primary Sclerosing Cholangitis)
Active, not recruiting·CCascade Pharmaceuticals, Inc·Phase 2·NCT05896137·50 enrolled
Study with Norucholic Acid Tablets in Patients with Primary Sclerosing Cholangitis (PSC)
Not yet recruiting·—·Phase 3·NCT06886360·120 enrolled
Investigation of Vancomycin Efficacy in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis
Not yet recruiting·MMcMaster University·Phase 2·NCT07341282·14 enrolled
Fecal Microbiota Transplantation for Primary Sclerosing Cholangitis - Randomized Study Versus Sham Transplantation
Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT07477782·72 enrolled
Efficacy and Safety of HK-660S in the Treatment of Primary Sclerosing Cholangitis
Not yet recruiting·CCuromeBiosciences·Phase 2·NCT06975150·105 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)